These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12422056)

  • 1. Moving forward: Herceptin in the adjuvant setting.
    Tan-Chiu E; Piccart M
    Oncology; 2002; 63 Suppl 1():57-63. PubMed ID: 12422056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
    Baselga J
    Oncology; 2001; 61 Suppl 2():14-21. PubMed ID: 11694783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
    Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Herceptin: the future in adjuvant breast cancer therapy.
    Piccart-Gebhart MJ
    Anticancer Drugs; 2001 Dec; 12 Suppl 4():S27-33. PubMed ID: 11989524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
    Slamon D; Pegram M
    Semin Oncol; 2001 Feb; 28(1 Suppl 3):13-9. PubMed ID: 11301370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
    Jahanzeb M
    Clin Breast Cancer; 2008 Aug; 8(4):324-33. PubMed ID: 18757259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Breast cancer: HER2 changes one's cards on the table].
    Lopez M
    Clin Ter; 2005; 156(5):255-62. PubMed ID: 16382976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Herceptin in primary breast cancer: views from North America and Europe.
    Leyland-Jones B; Smith I
    Oncology; 2001; 61 Suppl 2():83-91. PubMed ID: 11694792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future directions in the adjuvant treatment of breast cancer: the role of trastuzumab.
    Smith I
    Ann Oncol; 2001; 12 Suppl 1():S75-9. PubMed ID: 11521726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trials of new combinations of Herceptin in metastatic breast cancer.
    Thomssen C
    Anticancer Drugs; 2001 Dec; 12 Suppl 4():S19-25. PubMed ID: 11989523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between Herceptin and taxanes.
    Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
    Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical and economic issues in adjuvant chemotherapy for HER-2 positive breast cancer].
    Martins SJ; Yamamoto CA
    Rev Assoc Med Bras (1992); 2008; 54(6):494-9. PubMed ID: 19197525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose scheduling--Herceptin.
    Leyland-Jones B
    Oncology; 2001; 61 Suppl 2():31-6. PubMed ID: 11694785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer.
    Metcalfe S; Evans J; Priest G
    N Z Med J; 2007 Jun; 120(1256):U2593. PubMed ID: 17589560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer.
    Costa RB; Kurra G; Greenberg L; Geyer CE
    Ann Oncol; 2010 Nov; 21(11):2153-2160. PubMed ID: 20351072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies.
    Smith IE
    Anticancer Drugs; 2001 Dec; 12 Suppl 4():S3-10. PubMed ID: 11989525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab.
    Eniu A
    J BUON; 2007 Sep; 12 Suppl 1():S119-26. PubMed ID: 17935269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
    Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.